Linked Life Data

7912491

Source:http://linkedlifedata.com/resource/pubmed/id/7912491

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2A
pubmed:dateCreated
1994-7-25
pubmed:abstractText
Suramin at 100 to 800 micrograms/ml caused a dose dependent growth inhibition in three (Zr-75-1, BT 549 and HS-578T) parental human breast cancer cell lines and their corresponding sublines with acquired doxorubicin (dox) and multi-drug resistance. The effect was significantly more marked after 7 days suramin exposure compared with 3 days. The oestrogen and progesterone receptor rich cell line Zr-75-1 was more responsive to suramin compared with the other two lines. The sublines Zr-75-1-dox and HS-578T-dox with an increased expression of the permeability glycoprotein (P-gp) demonstrated a significantly decreased cell survival compared with corresponding parental cell lines at 3 and 7 days exposure of suramin, respectively. The subline BT 549-dox with multi-drug resistance without P-gp expression had a significantly impaired response after 3 days suramin compared with the parental line. These results indicate that suramin may be a potential therapeutic agent for the breast cancer patients with P-gp expression and multi-drug resistance.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0250-7005
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
363-6
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
Suramin inhibits the growth of human breast cancer cell lines. Studies on parental lines and corresponding sublines with acquired doxorubicin resistance with and without expression of P-glycoprotein.
pubmed:affiliation
Department of Oncology, Akademiska Sjukhuset, University of Uppsala, Sweden.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't